Physicians at the Brigham and Women's Hospital International Pleural Mesothelioma Program, one of the largest treatment programs in the world, have developed treatment to significantly extend the survival of patients with malignant pleural mesothelioma (MPM, which is currently between four and twelve months following diagnosis.
David Sugarbaker, MD, director of the program, has conducted multi-modality clinical trials combining advanced surgical resection by extrapleural pneumonectomy or pleurectomy with intrathoracic/intraperitoneal heated chemotherapy. This treatment has added years onto the lives of patients with MPM.
To learn more about the BWH International Pleural Mesothelioma Program, click here.
Send Feedback to: 
